Irinotecan drug eluting beads used as a treatment of advanced intra hepatic cholangiocarcinoma

Jean Amede Roch¹, John Palma-Gutierrez¹, Marie Georges Lapalus², Carole Paillet³, Frank Pilleul¹

¹. Département d’Imagerie Digestive, Hôpital Edouard Herriot. Hospices Civils de Lyon. Lyon - France
². Département d’Hépato gastro-entérologie, Hôpital Edouard Herriot. Hospices Civils de Lyon. Lyon - France
³. Département Pharmaceutique, Hôpital Edouard Herriot. Hospices Civils de Lyon. Lyon - France

* Correspondence: Frank Pilleul, Département d’Imagerie Digestive, Hôpital Edouard Herriot. Place d’Arsonval / 69003 Lyon - France. (frank.pilleul@chu-lyon.fr)

ABSTRACT

This report describes a 74-year-old male with unresectable intrahepatic cholangiocarcinoma (ICC). However surgical procedure is the only curative treatment, it often seems to be ineffective because of the aggressive behaviour of the disease. The role of systemic chemotherapy in the ICC is undefined with a median survival between 6.43 to 12.17 months obtained by using the combination chemotherapy of gemcitabine with cisplatin. In the present case, we performed a targeted treatment using drug eluting beads (DEB) with irinotecan (IRI) administered as transarterial-chemoembolization (TACE). After one session, the tumour vascularity decreased significantly at the one month evaluation on computed tomography (CT) scan of the liver. This case report suggested that minimally invasive transcatheter DEB embolization could be a promising, safe and effective treatment for selective patients with unresectable ICC.

CASE REPORT

Introduction:

Cholangiocarcinoma is a rare malignant tumour which carries a dismal prognosis, with low survival times. It is the second cause of primary liver cancer after hepatocellular carcinoma (1, 2), and composed of cells that arise from the biliary tract. Chronic biliary tract inflammation is known to be a risk factor for the development of ICC, such as primary sclerosing cholangitis, infection, or hepatolithiasis. Histologically, ICC is mostly well-differentiated adenocarcinoma, arising from a malignant transformation of epithelial cells (cholangiocytes) and classification is based on location divided into three categories (intra-hepatic tumours, extra-hepatic tumours, and distal locations). These different forms are distributed as follows: about 5-10% for intra-hepatic form, 60-70% for hilar tumours and 20-30% for common bile duct tumours (3). The Liver Cancer Study Group of Japan has suggested a classification using macroscopic features which are mass forming, periductal infiltration, intraduct growth, or mixed form (4, 5).

Treatment options are determined by the local extension, the vascular invasion, presence of metastasis, and the liver function. Although surgical complete resection remains the only curative treatment for ICC, most of the patients have advanced disease at the time of the diagnosis and are not eligible for surgical management. Adjuvant chemotherapy can be performed in case of unresectable ICC, but it efficacy remains controversial with no benefit in term of survival and tumor recurrence (6).

Recently, TACE using DEB with doxorubicin has been proposed as an alternative therapy for carcinoma (7). Drug eluting beads are an embolic microsphere product that is capable of being loaded with anthracycline drugs such as IRI just before administration in a TACE procedure. Advantages of this procedure are to stop arterial workflow for the tumour...
(ischemic step, tissue necrosis), to minimize systemic toxicity of the chemotherapy, and to offer the possibility of controlling the release and dose of the drug into the tumour bed (8). IRI is an active drug used frequently in the treatment of advanced colorectal cancer of first and second line. A recent study of the chemoembolization of rat colorectal liver metastases with IRI-DEB showed significant anti-tumoral activity (9).

We present a case of DEB with IRI administered by TACE in a patient with unresectable ICC.

**Case report:**

A 74-year-old male with history of myocardial infarction and sigmoiditis underwent an abdominal ultrasonography for right upper quadrant pain, which identified multiple liver lesions without bile duct dilatation (Fig. 1). A CT scan examination demonstrated nodular, diffuse and heterogeneous liver lesions with peripheral hypervascular appearance (Fig. 2). The greatest lesion was located within the segments IV and V; measuring 86 mm x 74 mm. A targeted liver biopsy was performed in the greatest lesion and microscopic analysis showed an ICC. Based on the CT scan results, multidisciplinary staff discussion confirmed the resectable approach was impossible. Patient was qualified for palliative systemic chemotherapy treatment with iterative sessions using the combination of gemcitabine with cisplatin (GEMZAR protocol) (10). However, this therapy not induced positive response and the greatest lesion in a new CT scan examination (5 months after initial CT scan) measured 100 mm x 74 mm.

A multidisciplinary approach decided to perform a DEB with IRI in a TACE, offering the patient another therapeutic strategy.

After explaining the benefits and risks of the TACE, we received the complete consent from the patient to proceed. Before TACE, patient received i.v. hydration, antibiotic prophylaxis, 500 mg of hydrocortisone, and antiemetic drug.

**Procedure:**

A 5-French desilet was inserted in the right femoral artery under local anesthesia. Prior to embolization, angiography of the hepatic and mesenteric artery was performed to map liver vascular anatomy, check for arteriovenous shunts, and identify arterial feeders of the tumour, which demonstrated many hypervascular nodular lesions (Fig. 3) in both lobes of the liver. The liver invasion of the biggest lesion was over 30%. Catheter was placed in the right hepatic artery with the use of a 2.7 Fr microcatheter (Progreat, Terumo) and injection of the load beads was performed.

DEB with the cytotoxic agent (Irinotecan 100 mg) was previously loaded by an experienced pharmacist two hours before the treatment, with 15 ml of drug eluting bead (size ranging from 200-400 microns). At the end of the injection, liver angiography control demonstrated the treatment’s efficacy and the tumor’s devascularization (Fig. 4). Patient presented a post embolization syndrome during three days (pain, fever, nausea and vomiting).

One month after TACE, a control CT was done and revealed significant decreased vascularity of the liver lesions in the liver’s right side (Fig. 5). Clinical evaluation demonstrated an increase in ascitis of 20%, which was attributed to the advanced state of the hepatic dysfunction.

**TEACHING POINT**

TACE with IRI- DEB was feasible, efficient and well tolerated, and we believe it is suitable to follow the investigation of Irinotecan as a new palliative treatment of unresectable ICC.
Interventional Radiology: Irinotecan drug eluting beads used as a treatment of advanced intra hepatic cholangiocarcinoma

Roch et al.

ABBREVIATIONS

ICC = Intrahepatic cholangiocarcinoma
DEB = Drug eluting beads
IRI = Irinotecan
TACE = Transarterial-chemoembolization
CT = Computed tomography
Fr = French

REFERENCES


FIGURES

Figure 1: Grayscale ultrasound of the liver demonstrates multiple liver lesions (arrow).
**Interventional Radiology:** Irinotecan drug eluting beads used as a treatment of advanced intra hepatic cholangiocarcinoma

**Figure 2:** Contrast enhanced CT scan in the arterial phase demonstrates nodular and heterogeneous liver lesions with peripheral hypervascular appearance (black star).

**Figure 3:** Selective proper hepatic angiogram demonstrates hypervascular intrahepatic masses (white star).

**Figure 4:** Selective angiography of the right hepatic artery after DEB’s injection.

**Figure 5:** Follow up contrast enhanced CT scan one month after DEB injection reveals development of necrosis and significant decrease of the lesions’ vascularization (black star).

URL of this article:

Published by EduRad
www.EduRad.org